drugset / Trial / NCT00071409

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

NCT00071409

Phase 2 Completed 63 enrolled Exsulin Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.

Timeline

Start
2003-10
Primary completion
2004-05
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject INGAP Peptide Peptide 300 mg Subcutaneous
Subject INGAP Peptide Peptide 600 mg Subcutaneous